All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
All‐cause mortality · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in all‐cause mortality compared with standard platelets (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · patients with solid tumours without thrombocytopenia before chemotherapy
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
All‐cause mortality · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
no estimate extracted
4 participants
GRADE not reported
All‐cause mortality · people with abnormal coagulation requiring a central venous catheter
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with paroxysmal nocturnal hemoglobinuria
1 finding from 1 review
Intervention not reported
All‐cause mortality [ · patients with polycythaemia vera
The intervention probably leads to lower all‐cause mortality [ (moderate certainty).
1 finding from 1 review
Intervention not reported
28‐day all‐cause mortality · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention probably leads to lower 28‐day all‐cause mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality Median · patients with indolent B cell lymphoid malignancy
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 45 · non‐hospitalised adults with mild COVID‐19
The intervention showed no clear difference in all‐cause mortality at day 45 (low certainty).
1 finding from 1 review
All‐cause mortality at day 28 · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.79 [0.43, 1.44]
Studies not reported
Low
All‐cause mortality by day 60 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in all‐cause mortality by day 60 compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in all‐cause mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in all‐cause mortality at day 28 (moderate certainty).
1 finding from 1 review
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review